Navigation Links
US Patent Allowed for NOD Tech
Date:11/24/2009

SHANGHAI, Nov. 24 /PRNewswire-Asia/ -- NOD Pharmaceuticals Inc. announced the US Patent & Trademark Office (PTO) has allowed the patent application for its nano-particle oral delivery or NOD technology.

NOD technology is a highly efficient approach to incorporate peptides or proteins into bio-adhesive nano-particles to enable oral delivery of drugs otherwise administered as injections. NOD technology is a platform technology that can be applied to many macromolecular drugs such as insulin, interferon, growth hormone, exenatide, heparin and more.

Currently, an oral insulin formulation, the first candidate developed with NOD technology, is entering phase I clinical studies in China.

"Patent allowance for NOD technology is a major step forward for NOD", quoted from William Lee, CEO. "With this patent, and in combination with others, NOD is building a solid foundation for its intellectual property and core competence."

    For more information, please contact:

     William Lee, Ph.D., CEO
     Phone: +86-21-6194-0758
     Email: info@nodpharm.com


    Notes for Editors

About NOD Pharmaceuticals

NOD Pharmaceuticals, Inc. is a development stage biotech company and emerging leader in innovative delivery for biopharmaceuticals. NOD uses patented platform technology, nano-particle oral delivery or NOD technology, to develop oral formulations for biopharmaceuticals, including insulin, exenatide, interferon, human growth hormone and more.

More information can be found at http://www.nodpharm.com .

SOURCE NOD Pharmaceuticals, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information
2. BioLife Solutions Granted Japanese Biopreservation Patent
3. Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment
4. AvidBiotics Corp. Granted Key U.S. and European Patents on Unique Protein Modification Platform
5. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
6. Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes
7. Athera Receives Allowance of Two Key Patents
8. Jeremy M. Stipkala to Lead Symposium Entitled Patent Law Developments at SERMACS 2009
9. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
10. ER Doctor Demonstrates Breast Pump on Live TV with Patented New Freemie Hands-Free System
11. Martek Announces Settlement of Patent Dispute with Capsugel France
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 2017 Ginkgo Bioworks, the organism company, ... in the synthesis and assembly of DNA. The ... pathway-length synthetic DNA into Ginkgo,s automated organism engineering ... construction of new organism designs for application across ... was founded to significantly increase the world,s capacity ...
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 ... formation of its Medical/Clinical Advisory Board.  This new ... who enhance the range and depth of expertise ... its novel prenatal diagnostic tests.  These experts are ... guidance for the company,s product development and commercialization ...
(Date:1/19/2017)... and GAITHERSBURG, Md. , ... PIP) and Altimmune, Inc., a privately-held immunotherapeutics company ... a definitive agreement for the merger of PharmAthene ... investors include Novartis Venture Fund, HealthCap, Truffle Capital ... a fully-integrated and diversified immunotherapeutics company with four ...
(Date:1/19/2017)... NY (PRWEB) , ... January 19, 2017 , ... FireflySci ... an exponential rate. The tremendous growth is accounted to two main factors. ... table and the expanding network of vendors supplying FireflySci products all around the world. ...
Breaking Biology Technology:
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... Forecasts, 2015 - 2022," projects that the global biometric technology market is expected to ... 2016 to 2022. Continue Reading ... ...      ...
(Date:1/6/2017)... 6, 2017  Privately-held CalciMedica, Inc., announced that ... volunteers of a novel calcium release-activated calcium (CRAC) ... Acute pancreatitis, sudden painful inflammation ... but can be very serious.  In severe cases it ... extended hospital stays, time in the ICU and ...
(Date:1/4/2017)... of attendees at this year,s International Consumer Electronics Show (CES), A&D ... and services, will be featuring its new line of ULTRA CONNECT ... CES Exhibit Suite , the new upper arm and wrist smart blood ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):